ISRCTN87502816已完成3 期
A multicentre, controlled phase III study to compare the efficacy and safety of VIT-45 and Venofer® in the treatment of iron deficiency anaemia associated with chronic renal failure in patients on haemodialysis
Vifor Pharma (Switzerland)0 个研究点目标入组 183 人开始时间: 2009年1月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 183
研究概览
简要总结
2008 conference abstract in https://doi.org/10.1093/ckj/1.suppl_2.ii232 (MP375, p.360) (added 14/02/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adult, male or female, between the ages of 18 and 80 years (inclusive) requiring haemodialysis/haemodiafiltration with iron deficiency secondary to chronic renal failure
- •2. IDA defined as haemoglobin (Hb) less than or equal to 115 g/L and at least one of the following:
- •2.1. Transferrin saturation (TfS) less than 20%
- •2.2. Serum ferritin less than 200 µg/L
- •Initially, a total of 120 patients (60 in each treatment group) were enrolled with a Hb value of less than or equal to 100 g/L. Following amendment 2, this was adjusted such that in each treatment group at least 50% of patients (at least 60 in each treatment group) were enrolled with a Hb value of less than or equal to 100 g/L
- •3. Patients treated with EPO (including epoetin alfa, epoetin beta, and darbepoetin alfa) must have received this treatment for at least 8 weeks prior to inclusion in the study. The EPO dose may have been decreased during the study at the discretion of the investigator; increases in the dose of EPO were not permitted.
- •4. Permanent vascular access appropriate for haemodialysis/haemodiafiltration
- •5. Females of childbearing potential must have had a negative serum pregnancy test at screening and agreed to practise an acceptable method of birth control during the study and for up to one month after the last dose of the study medication. Acceptable methods of birth control included barrier methods (including male and female condoms), diaphragms (cervical caps) with intravaginal spermicide (including jellies, foams and suppositories), intra-uterine devices or hormonal contraceptives. Non-childbearing potential included being surgically sterilised at least 6 months prior to the study or post-menopausal with no menstrual bleeding for at least 2 years prior to the study. Fertile males agreed to ensure that they use adequate contraception during the study.
- •6. Demonstrated the ability to understand the requirements of the study, willingness to provide written informed consent, abide by the study restrictions, and agree to return for the required assessments
排除标准
- •1. Body weight less than 40 kg
- •2. Blood transfusion or oral or parenteral iron treatment within 30 days prior to enrolment, or anticipated need for a blood transfusion during the study
- •3. Documented hypersensitivity to components of VIT-45 or Venofer®
- •4. Other types of anaemia (especially haemolytic, macrocytic, hypoplastic, or sideroblastic anaemia)
- •5. Haemochromatosis or other iron storage disorders. Addition of haemodiafiltration was introduced following protocol amendment 1.
- •6. Untreated vitamin B12 or folic acid deficiency (deficiency defined as below the normal range). Patients with subnormal vitamin B12 levels were included if all of the following criteria are met:
- •6.1. No suspicion of atrophic gastritis
- •6.2. No history of resection of large parts of the stomach or upper intestine
- •6.3. Treatment of vitamin B12 deficiency was started prior to randomisation
- •7. Treatment with an investigational drug within the 30 days prior to enrolment
- •8. History of addiction to drugs or chronic alcohol abuse
- •9. Prior use of VIT-45 or prior participation in other studies of VIT-45
- •10. Myelosuppressive therapy or need for surgery
- •11. Active severe infection or malignancy other than carcinoma in situ of the cervix and non-melanoma skin cancer
- •12. Active liver disease. Patients who were positive for hepatitis B surface-antigen (HbsAg) or hepatitis C virus antibody (anti-HCV) were excluded if they had abnormal liver function test (LFT) results
- •13. Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure (New York Heart Association grade III or IV), or poorly controlled hypertension according to the judgement of the investigator
- •14. Positive for human immunodeficiency virus-1 (HIV)-1/HIV-2 antibodies (anti-HIV)
- •15. Pregnant women or nursing mothers
- •16. Endocrinologic or metabolic disorders that were not controlled
研究者
相似试验
招募中
不适用
TEAM II A randomised, multicentre, prospective, phase III trial investigating TEAM IIa: Neoadjuvant hormonal therapy with exemestane for three versus six months. and / or TEAM IIb: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer.Breast Cancer, Neoadjuvant hormonal therapy, Aromatase inhibitor, Adjuvant therapy, BisphosphonatesNL-OMON27856TEAM II Study Group2,478
已完成
3 期
A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancerocally advanced and metastatic pancreatic cancerLocally advanced and metastatic pancreatic cancerCancerISRCTN43482138The University of Liverpool (UK)1,062
撤回
3 期
A phase 3 prospective, multicenter study to evaluate efficacy and safety of rVWF with or without ADVATE in elective surgical procedures in subjects with severe von Willebrand diseaseextended or excessive bleeding10035534NL-OMON42081Baxalta Innovations GmbH2
已完成
3 期
IgNiTE: Immunoglobulin in the treatment of encephalitisEncephalitisNervous System DiseasesEncephalitis, myelitis and encephalomyelitis, unspecifiedISRCTN15791925niversity of Oxford18
已完成
3 期
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaDyslipidemiasHypertensionNCT04074551Hanmi Pharmaceutical Company Limited145